Earnings ·
AbbVie updated its 2026 earnings guidance to include an expected $744 million pre-tax charge for acquired IPR&D and…
ABBVAbbVie Inc.
AbbVie updated its 2026 earnings guidance to include an expected $744 million pre-tax charge for acquired IPR&D and milestone expenses in the first quarter. This expense will reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.41 for the quarter, resulting in a revised full-year 2026 adjusted diluted EPS guidance range of $13.96 to $14.16. This update is significant for investors as it clarifies the immediate impact of recent research and development investments and collaborations on the company's profitability.